Net stock forecast the net stock forecast shows the

The net stock forecast shows the healthcare sector stable despite policy headwinds. Large-cap pharma stocks reported 5% EPS growth in Q1, driven by strong overseas sales, balancing regulatory cost pressures in domestic markets. 24% = US$836m ÷ US$3.5b (Based on the trailing twelve months to June 2025). The stock has delivered stellar returns so far in 2025 as it posted solid Q4 2024 earnings and guidance. It posted 27% year-over-year revenue growth to $459.9 million and it added 55 new $1 million+ annual customers in 2024. The net stock forecast anticipates continued growth in renewable energy stocks, with wind and solar producers reporting double-digit order backlogs. Carbon credit price increases may provide additional upside over the medium-term for ESG-focused portfolios.